Potential role of targeted therapies in the treatment of triple-negative breast cancer
MetadataShow full item record
Breast cancer is the most common cancer type that affects women and is the major cause of morbidity and mortality. Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype and accounts for 10–20% of all breast cancer cases. TNBC is commonly characterized by the absence of estrogen, progesterone, and the Her2/neu receptor and is usually diagnosed by immunohistochemistry. Mutations in the BRCA1 gene, as well as overexpression of oncogenic kinases, such as human epidermal growth factor receptor 2, vascular endothelial growth factor-A, insulin-like growth factor-1 (IGF-1)/IGF-1 receptor, and transforming growth factor-β1, have been found to be correlated with a higher risk of metastasis and poor overall survival in TNBC patients. The current review briefly discusses the various treatment options including chemotherapeutics and targeted therapies that are available currently for the therapy of TNBC patients and highlights their comparative benefits and disadvantages for clinical application.
Showing items related by title, author, creator and subject.
Datta, A.; Loo, S.; Huang, B.; Wong, L.; Tan, S.; Tan, T.; Lee, S.; Thiery, J.; Lim, Y.; Yong, W.; Lam, Y.; Kumar, Alan Prem; Yap, C. (2014)Triple-negative breast cancer (TNBC) is characterized by unique aggressive behavior and lack of targeted therapies. Among the various molecular subtypes of breast cancer, it was observed that TNBCs express elevated levels ...
Shah, S.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; Bashashati, A.; Prentice, L.; Khattra, J.; Burleigh, A.; Yap, D.; Bernard, V.; McPherson, A.; Shumansky, K.; Crisan, A.; Giuliany, R.; Heravi-Moussavi, A.; Rosner, J.; Lai, D.; Birol, I.; Varhol, Richard; Tam, A.; Dhalla, N.; Zeng, T.; Ma, K.; Chan, S.; Griffith, M.; Moradian, A.; Cheng, S.; Morin, G.; Watson, P.; Gelmon, K.; Chia, S.; Chin, S.; Curtis, C.; Rueda, O.; Pharoah, P.; Damaraju, S.; MacKey, J.; Hoon, K.; Harkins, T.; Tadigotla, V.; Sigaroudinia, M.; Gascard, P.; Tlsty, T.; Costello, J.; Meyer, I.; Eaves, C.; Wasserman, W.; Jones, S.; Huntsman, D.; Hirst, M.; Caldas, C.; Marra, M.; Aparicio, S. (2012)Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in ...
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerDent, R.; Lindeman, G.; Clemons, M.; Wildiers, H.; Chan, Arlene; McCarthy, N.; Singer, C.; Lowe, E.; Watkins, C.; Carmichael, J. (2013)Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic ...